OCD Global Prevalence: WHO Statistics and Clinical Context

According to the World Health Organization (WHO), obsessive-compulsive disorder (OCD) affects ~2.3% of the global population (approximately 175 million people), making it one of the top 20 causes of disability worldwide.

Epidemiology

• Gender: Roughly equal prevalence; males earlier onset (childhood/adolescence), females later (early adulthood).
• Onset: Bimodal — childhood (10–12) and early adulthood (20–30); rare after 40.
• Comorbidity: High — major depression (60%), anxiety disorders (30%), tic disorders (30%), body dysmorphic disorder, eating disorders.
• Course: Chronic, waxing/waning; <10% spontaneous remission.

Global Burden

• YLDs (years lived with disability): OCD ranks in top 10 for ages 15–44.
• Economic: Direct (treatment) + indirect (lost productivity) costs substantial.
• Treatment gap: <35% receive minimally adequate treatment (WHO).

Evidence-Based Treatment

• CBT with ERP (exposure and response prevention): First-line, effect size large.
• SSRIs: Fluoxetine, sertraline, fluvoxamine, paroxetine, escitalopram, citalopram — higher doses, longer trials (12 wks) than depression.
• Combination: CBT-ERP + SSRI superior to either alone for moderate-severe.
• Augmentation: Atypical antipsychotics (risperidone, aripiprazole) for partial response.
• Neuromodulation: Deep TMS (FDA-cleared), DBS (refractory).

Public Health Implications

• Early detection (screening in primary care, schools).
• Training non-specialists in ERP basics.
• Reducing stigma (OCD ≠ "being neat").
• Integrating mental health into universal health coverage.

OCD is common, disabling, and treatable. Closing the treatment gap is a global priority.